Bronx, NY, United States
Bronx, NY, United States

Time filter

Source Type

Patent
Varian Medical Systems and Montefiore Medical Center | Date: 2016-03-07

Disclosed are methods of obtaining an expanded population of mammalian ex vivo cells for treating a mammalian subject by (a) administering to a subject an effective amount of an agent that confers a growth disadvantage to at least a subset of endogenous cells at the site of engraftment; (b) administering to the subject an effective amount of a mitogenic stimulus for the ex vivo cells; and (c) administering the ex vivo cells to the subject, wherein the ex vivo cells engraft at the site and proliferate to a greater extent than the subset of endogenous cells, to repopulate at least a portion of the engraftment site with the ex vivo cells. The repopulated cells can be harvested or left at the engraftment site. Methods of treating brain injury in a subject by engrafting ex vivo cells at the site of injury are also described.


Francis D. Baudry, MD, Psychiatrist and Psychoanalyst with his own practice, and affiliated with Mount Sinai Medical Center, and on the faculty of the New York Psychoanalytic Institute where he is a Training and Supervising analyst has been named a 2017 Top Doctor in New York City, New York. Top Doctor Awards is dedicated to selecting and honoring those healthcare practitioners who have demonstrated clinical excellence while delivering the highest standards of patient care. He is also a member of the Soldier’s project, an organization dedicated to giving free mental health care to veterans and their families. Dr. Francis D. Baudry was born in France and speaks fluent French and treats patients in both French and English. He is a vastly experienced psychiatrist, having been in practice for more than six decades. His long and successful career in psychiatry began in 1955, when he graduated from the New York University School of Medicine. After an internship at the Albert Einstein-Montefiore Medical Center, Dr. Baudry returned to New York University to complete his residency. Dr. Baudry is board certified by the American Board of Psychiatry and Neurology, and is renowned across New York and beyond as a specialist in psychiatry and in psychoanalysis. He has lectured widely in England, France, Italy and Israel. With his wealth of experience to call upon, Dr. Baudry diagnoses and treats a wide range of conditions, from anxiety and depressive disorder, to post traumatic stress disorder, psychosomatic conditions and  borderline personality disorders. He also has a special interest in issues of creativity and its inhibitions both in literature and in the visual arts. Dr. Baudry has written many papers on topics ranging from liaison psychiatry to the art of supervision, character issues, the analytic encounter, applied psychoanalysis ( visual arts , poetry, novels and theater). He is also quite knowledgeable in French psychoanalysis and has written on the contribution of Andre Green.He is always happy to help mentor and advise less experienced colleagues and his dedication and commitment makes Dr. Francis D. Baudry a very worthy winner of a 2017 Top Doctor Award. Top Doctor Awards specializes in recognizing and commemorating the achievements of today’s most influential and respected doctors in medicine. Our selection process considers education, research contributions, patient reviews, and other quality measures to identify top doctors.


Patent
University of Arkansas, The Kitasato Institute and Montefiore Medical Center | Date: 2016-12-21

Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. Methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. In addition, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.


SEATTLE, WA--(Marketwired - May 11, 2017) - Atossa Genetics, Inc. ( : ATOS) today announced First Quarter ended March 31, 2017 financial results and provided an update on recent company developments. Steve Quay, President and CEO, commented, "We are encouraged by our positive progress in advancing the endoxifen program with our ongoing Phase 1 endoxifen study and pleased that our fulvestrant microcatheter study is proceeding at Montefiore Medical Center. We look forward to completing our endoxifen Phase 1 study in the next quarter and commencing a Phase 2 study in the second half of 2017." We are in the research and development phase and do not generate revenue. Operating expenses: Total operating expenses were approximately $1.7 million for the three months ended March 31, 2017, consisting of general and administrative (G&A) expenses of approximately $1.1 million and R&D expenses of approximately $544,000. Operating expenses for the three months ended March 31, 2017 decreased approximately $641,000, or 27.5%, from approximately $2.3 million for the three months ended March 31, 2016, which consisted of G&A expenses of approximately $2.2 million, and R&D expenses of approximately $150,000. The Company recorded a net loss of $1.7 million, for the three months ended March 31, 2017, as compared to a net loss of $2.3 million for the three months ended March 31, 2016. Atossa Genetics, Inc., is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com. Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, results of clinical studies, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others, such as patent rights, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.


CRANBURY, N.J.--(BUSINESS WIRE)--Clostridium difficile infections cause serious symptoms that range from diarrhea to life-threatening inflammation of the colon. Approximately 30,000 Americans die within one month of the infection being diagnosed, and new evidence reveals that emerging, more virulent strains (that are also more difficult to treat) are leading to higher mortality rates. Hospitals and nursing homes are two settings in which Clostridium difficile infections notably transpire, mainly because of their high levels of bacteria exposure. However, the infection now is becoming more prevalent in communities, as well, and primary care physicians are increasingly concerned. The infection is especially harmful for patients who have medical conditions that have weakened their immune system, such as inflammatory bowel disease and colorectal cancer, or who are undergoing serious treatments like chemotherapy. In an effort to raise awareness about the risks of Clostridium difficile infection and to instruct the public and health care professionals on ways to prevent or manage the condition, MD Magazine® recently connected key opinion leaders in the field during the expert panel discussion, “Managing Clostridium Difficile Infections In the Community.” As scrutinized throughout this Peer Exchange®, evidence demonstrates increasing rates of the infection in populations of patients that have no common risk factors. “What’s interesting about the community cases is that they’re occurring in a group of people that, heretofore, were not recognized to be at risk for this disease,” remarked Lawrence J. Brandt, MD, Albert Einstein College of Medicine and Montefiore Medical Center. Throughout the 16-part series, available at http://www.mdmag.com/peer-exchange/clostridium-difficile-infections, Dr Brandt and colleagues consider Clostridium difficile infection risk factors and potential community sources and highlight top strategies in the diagnosis and management of the potentially chronic condition. They also provide insight on promoting antibiotic stewardship, including information on high-risk versus low-risk antibiotics. Among the educational points is an emphasis on the high rate of recurrence. “Unfortunately, many people are not informed that this could come back, and lots of those people (where it does come back) end up in the hospital just because diarrhea came back and they didn’t know to call someone,” noted Erik Dubberke, MD, Washington University School of Medicine. MD Magazine® is a comprehensive clinical news and information portal that provides physicians and other health care professionals with up-to-date specialty- and disease-specific resources designed to help them provide better care to patients. Readers have access to breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice-management updates, and insight and analysis from physician contributors and other multimedia resources. MD Magazine® is part of Michael J. Hennessy Associates, Inc., a full-service health care communications company offering education, research and medical media. For more information, please visit: http://www.mdmag.com/


News Article | April 28, 2017
Site: www.PR.com

Receive press releases from U.S. Veg Corp.: By Email U.S. Veg Corp Brings the 7th Annual NYC Veg Food Fest to Manhattan New York, NY, April 28, 2017 --( Kristin LaJeunesse is the founder of an award-winning website and the memoir Will Travel for Vegan Food: A Young Woman's Solo Van-Dwelling Mission to Break Free, Find Food, and Make Love. She is now focused on creating the first nationally-televised vegan travel show. Her talk will be featured on day one of the festival. Along with scrumptious food stories, she’ll let people in on exactly what it’s like to maintain a location-independent lifestyle indefinitely. Another social media guru to be featured is Ellen Kanner who will speak on "Garden of Earthly Delights: Fueling Passion with Plants." She is the author of Feeding the Hungry Ghost, and is also the Huffington Post’s Meatless Monday blogger and a syndicated columnist for The Edgy Veggie. A recipe developer for numerous other publications, her talk promises to be filled with mouth-watering treats. Several of the other headliners on tap will give a medical slant to their presentations. Dr. Robert Ostfeld will speak on "Confessions of a Reformed Cardiologist: A Plant-Based Diet and Your Heart.” Ostfeld is associate professor of Clinical Medicine at Albert Einstein College of Medicine, director of the Cardiac Wellness Program at Montefiore Medical Center, and associate director of the Cardiology Fellowship at Montefiore-Einstein. He received his training from the University of Pennsylvania, Yale University School of Medicine, the Harvard School of Public Health, and Harvard Medical School. Dr. Chiti Parikh will zero in on the “Gut Microbiome and Your Health.” She is an assistant professor at Weill Cornell Medical College where she plays an active role in medical education, research and patient care. She is also the co-founder of the Integrative Health program at New York PresbyterianHospital, which provides services such as acupuncture, meditation, yoga, nutrition, psychotherapy, and biofeedback. Dr. Casey Taft is co-owner of Vegan Publishers and a professor of psychiatry at Boston University School of Medicine. He’s an internationally recognized researcher in the area of violence and abuse prevention, and has published over 100 journal articles, book chapters, and scientific reports. He recently authored Motivational Methods for Animal Advocacy: A Clinical Psychology Perspective. His upcoming book is Millennial Vegan: Tips for Navigating Relationships, Wellness, and Everyday Life as a Young Animal Advocate, which will be the focus of his festival talk. Many more speakers will grace the festival stages, including animal rights organizers, vegan chefs, and vegan athletes. There will be cooking demonstrations and book signings. A special area of the festival grounds will be devoted to children’s activities. There will be a variety of entertainment as well, including a performance by the Edward Morgan Ballet and a screening of the short documentary film Home on the Range. For many attendees, however, the main attraction will be the chance to sample and buy wares from the scores of plant-based vendors that will fill the festival space. Main courses, desserts, snacks and condiments will be showcased along with apparel, beauty products, and other vegan lifestyle items. The New York City Vegetarian Food Festival is presented by U.S. Veg Corp, a production and marketing company which also founded and produces the Arizona and California Vegetarian Food Festivals. Additionally, it produces other plant-based events throughout the year including various vegan food competitions, Vegan Drinks Brooklyn, and other smaller scale events. For more information on the upcoming festival or to purchase tickets, please visit http://nycvegfoodfest.com. New York, NY, April 28, 2017 --( PR.com )-- A traveler well on her way to sampling bites at every vegan restaurant in America will be one of the featured speakers at the 7th annual NYC Vegetarian Food Festival, May 20-21, at the Metropolitan Pavilion in Manhattan.Kristin LaJeunesse is the founder of an award-winning website and the memoir Will Travel for Vegan Food: A Young Woman's Solo Van-Dwelling Mission to Break Free, Find Food, and Make Love. She is now focused on creating the first nationally-televised vegan travel show. Her talk will be featured on day one of the festival. Along with scrumptious food stories, she’ll let people in on exactly what it’s like to maintain a location-independent lifestyle indefinitely.Another social media guru to be featured is Ellen Kanner who will speak on "Garden of Earthly Delights: Fueling Passion with Plants." She is the author of Feeding the Hungry Ghost, and is also the Huffington Post’s Meatless Monday blogger and a syndicated columnist for The Edgy Veggie. A recipe developer for numerous other publications, her talk promises to be filled with mouth-watering treats.Several of the other headliners on tap will give a medical slant to their presentations.Dr. Robert Ostfeld will speak on "Confessions of a Reformed Cardiologist: A Plant-Based Diet and Your Heart.” Ostfeld is associate professor of Clinical Medicine at Albert Einstein College of Medicine, director of the Cardiac Wellness Program at Montefiore Medical Center, and associate director of the Cardiology Fellowship at Montefiore-Einstein. He received his training from the University of Pennsylvania, Yale University School of Medicine, the Harvard School of Public Health, and Harvard Medical School.Dr. Chiti Parikh will zero in on the “Gut Microbiome and Your Health.” She is an assistant professor at Weill Cornell Medical College where she plays an active role in medical education, research and patient care. She is also the co-founder of the Integrative Health program at New York PresbyterianHospital, which provides services such as acupuncture, meditation, yoga, nutrition, psychotherapy, and biofeedback.Dr. Casey Taft is co-owner of Vegan Publishers and a professor of psychiatry at Boston University School of Medicine. He’s an internationally recognized researcher in the area of violence and abuse prevention, and has published over 100 journal articles, book chapters, and scientific reports. He recently authored Motivational Methods for Animal Advocacy: A Clinical Psychology Perspective. His upcoming book is Millennial Vegan: Tips for Navigating Relationships, Wellness, and Everyday Life as a Young Animal Advocate, which will be the focus of his festival talk.Many more speakers will grace the festival stages, including animal rights organizers, vegan chefs, and vegan athletes. There will be cooking demonstrations and book signings. A special area of the festival grounds will be devoted to children’s activities.There will be a variety of entertainment as well, including a performance by the Edward Morgan Ballet and a screening of the short documentary film Home on the Range.For many attendees, however, the main attraction will be the chance to sample and buy wares from the scores of plant-based vendors that will fill the festival space. Main courses, desserts, snacks and condiments will be showcased along with apparel, beauty products, and other vegan lifestyle items.The New York City Vegetarian Food Festival is presented by U.S. Veg Corp, a production and marketing company which also founded and produces the Arizona and California Vegetarian Food Festivals. Additionally, it produces other plant-based events throughout the year including various vegan food competitions, Vegan Drinks Brooklyn, and other smaller scale events.For more information on the upcoming festival or to purchase tickets, please visit http://nycvegfoodfest.com. Click here to view the list of recent Press Releases from U.S. Veg Corp.


Rabbani F.,Montefiore Medical Center
Cancer | Year: 2011

BACKGROUND: Male urethral cancer is a rare neoplasm, with the published literature consisting of small single-institution retrospective series. As such, there is no objective analysis of prognostic factors and treatment outcome. The author sought to use the population-based Surveillance, Epidemiology, and End Results (SEER) database to evaluate prognostic factors in male urethral cancer. METHODS: From 1988 to 2006, 2065 men were identified in the SEER database as having primary urethral cancer. Median follow-up was 2.5 years. Cancer-specific and overall survival was computed using the Kaplan-Meier method, and Cox proportional hazards analysis was used to evaluate patient age at diagnosis, year of diagnosis, race, histologic type, grade, T stage, nodal status, M stage, extent of surgery, and type of radiation as potential significant independent predictors of survival. RESULTS: Overall survival at 5 and 10 years was 46.2% (95% confidence interval [CI], 43.9-48.6%) and 29.3% (95% CI, 26.6-32.0%), respectively, whereas cancer-specific survival at 5 and 10 years was 68.0% (95% CI, 65.5-70.5%) and 60.1% (95% CI, 57.0-63.2%), respectively. Advanced age, higher grade, higher T stage, systemic metastases, other histology versus transitional cell carcinoma (TCC), and no surgery versus radical resection were predictors of death and death from disease, whereas adenocarcinoma was associated with a lower likelihood of death and death from disease as compared with TCC. In addition, nodal metastasis was a predictor of death. Surgery had a better outcome than radiation for stage T2-T4 nonmeta-static disease. CONCLUSIONS: Age, grade, TNM stage, histology, and extent of surgery were predictive of overall and cancer-specific survival. © 2010 American Cancer Society.


Klampfer L.,Montefiore Medical Center
Current Cancer Drug Targets | Year: 2011

Patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease, are at increased risk of developing colon cancer, confirming that chronic inflammation predisposes to development of tumors. Moreover, it appears that colon cancers that do not develop as a complication of inflammatory bowel disease are also driven by inflammation, because it has been shown that regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) lowers the mortality from sporadic colon cancer and results in regression of adenomas in familial adenomatous polyposis (FAP) patients, who inherit a mutation in the Apc gene. Colorectal cancer therefore represents a paradigm for the link between inflammation and cancer. Inflammation is driven by soluble factors, cytokines and chemokines, which can be produced by tumor cells themselves or, more often, by the cells recruited to the tumor microenvironment. Inflammatory cytokines and chemokines promote growth of tumor cells, perturb their differentiation, and support the survival of cancer cells. Tumor cells become addicted to inflammatory stroma, suggesting that the tumor microenvironment represents an attractive target for preventive and therapeutic strategies. Proinflammatory cytokines, such as TNFα, IL-6 and IL-1β, or transcription factors that are required for signaling by these cytokines, including NF-κB and STATs, are indeed emerging as potential targets for anticancer therapy. TNFα antagonists are in phase I/II clinical trials and have been shown to be well tolerated in patients with solid tumors, and IL-1β antagonists that ameliorate several inflammatory disorders characterized by excessive IL-1β production, will likely follow. Therefore, development of drugs that normalize the tumor microenvironment or interrupt the crosstalk between tumor and the tumor microenvironment is an important approach to the management of cancer. © 2011 Bentham Science Publishers Ltd.


Patent
Montefiore Medical Center | Date: 2016-01-12

Systems and methods are described for a sternal osteotomy guide and sternal fixation system.


Methods and compositions using 1,3-dicarbonyl compounds are disclosed for treating toxicity due to therapeutic agents and agents that causes oxidative cellular damage and for treating liver ischemia-reperfusion injury, as well as diseases and disorders that are improved through administration of N-acetylcysteine.

Loading Montefiore Medical Center collaborators
Loading Montefiore Medical Center collaborators